Skip to content

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Passed both chambers: it can still change before the session ends.

US HR 8205 · House Bill · 119th Congress

Stage
Passed both chambers
Started in
House
Sponsors
104
Latest action
Sep 28, 2026

What it does

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a…

Official summary · Reported to House · Jul 9, 2026

Titles and provisions can change as the bill moves.

Read the full textRead it on the official site

Where it stands

  1. Introduced (Done)

    Apr 6, 2026

  2. Committee (Done)

  3. Floor (Current step)

    Passed both chambers · Sep 28, 2026

  4. Law (Not started)

What moved

Loading recorded actions…

Who is involved

Sponsors

The lawmakers who put their names on it, lead sponsors first.

In the news

Reporting that may mention this subject. Possible matches are labeled.

Loading coverage…

Where it goes next

While a bill can still move, the questions are about people and money.

Work with this bill

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 | 52